Showing 4751-4760 of 9406 results for "".
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- RoC Skincare Expands The Look Forward Project to Instill Optimism Among the Next Generationhttps://practicaldermatology.com/news/roc-skincare-expands-the-look-forward-project-to-instill-optimism-among-the-next-generation/2461905/RoC Skincare is expanding The RoC Look Forward Project in partnership with Sarah Jessica Parker. The initiative was first launched in 2022 to celebrate the power of optimism and its positive impact on long-term health and wellbeing. Now, the Look Forward
- Curology Survey: Back-to-School Skin Woes Plague Studentshttps://practicaldermatology.com/news/curology-survey-back-to-school-skin-woes-plague-students/2461903/When thinking of going back to school, nearly 72% of students report feeling the pressure to look "perfect" by higher beauty standards set by social media, according to a survey of 2,000 American teens and young adults sponsored by Curology. What’s more, 25% of students
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and accept
- A Clinician's Guide to Alopecia: Diagnosis, Treatment, and Preventionhttps://practicaldermatology.com/news/a-clinicians-guide-to-alopecia-diagnosis-treatment-and-prevention/2461898/Hair loss, also known as alopecia, is a prevalent condition that affects people across every demographic.1 Unlike other skin issues that may remain unnoticed for extended periods, hair loss is often immediately apparent to the patient. Recently, alopecia has gained significant media at
- Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Developmenthttps://practicaldermatology.com/news/sirnaomics-appoints-dr-francois-lebel-as-senior-vice-president-for-preclinical-and-clinical-development/2461896/Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd. "With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarkin
- Practical Dermatology® Unveils New Cover Redesign for July 2023 Issuehttps://practicaldermatology.com/news/practical-dermatology-unveils-new-cover-redesign-for-july-2023-issue/2461895/Bryn Mawr Communications, publisher of Practical Dermatology®, has announced a captivating new cover redesign for the magazine, which will debut with their upcoming July issue. This visual update signals the first of many changes coming to the publication. "We are thrilled to unveil our s
- Research Validates Atopic March Patternhttps://practicaldermatology.com/news/research-validates-the-atopic-march/2461889/New research validates a population-level pattern of the “allergic march” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The average peak age of onset was approximately four months for eczema, 13 months
- Low Vitamin D Status Linked to PsO Severityhttps://practicaldermatology.com/news/low-vitamin-d-status-linked-to-pso-severity-2/2461887/Vitamin D levels may play a role in psoriasis severity, according to one of the largest studies to date. The analysis, which included almost 500 psoriasis cases from the National Health and Nutrition Examination Survey (NHANES), showed a linear relationship between increasing psoriasis
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy